No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis
Abstract Objective Patients with cystic fibrosis are more susceptible than members of the general population to lung infections. Infections with Pseudomonas aeruginosa require particular attention, because they may accelerate the deterioration of lung function if not adequately treated. This study a...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-03-01
|
Series: | BMC Research Notes |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13104-019-4157-8 |
id |
doaj-808d176250db41aa99599a56487ae1cf |
---|---|
record_format |
Article |
spelling |
doaj-808d176250db41aa99599a56487ae1cf2020-11-25T00:06:35ZengBMCBMC Research Notes1756-05002019-03-011211610.1186/s13104-019-4157-8No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosisF. Claude0I. Rochat1G. M. Hafen2Faculty of Biology and Medicine, University of LausanneDepartment of Pediatrics, Respiratory Unit, Centre Hospitalier Universitaire VaudoisDepartment of Pediatrics, Respiratory Unit, Centre Hospitalier Universitaire VaudoisAbstract Objective Patients with cystic fibrosis are more susceptible than members of the general population to lung infections. Infections with Pseudomonas aeruginosa require particular attention, because they may accelerate the deterioration of lung function if not adequately treated. This study assessed the eradication rate of P. aeruginosa primoinfections, with a protocol of inhaled tobramycin and oral ciprofloxacin over a 3 months’ period. Results Retrospective single-center study from June 1st, 2007 to December 31st, 2015. Inclusion of 28 pediatric patients (11 females, 17 males), with a total of 49 primoinfections. Overall success rate of 67.3%, which is similar or even inferior to figures published in the literature.http://link.springer.com/article/10.1186/s13104-019-4157-8Cystic fibrosisPseudomonas aeruginosaPrimoinfectionEradication protocol |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
F. Claude I. Rochat G. M. Hafen |
spellingShingle |
F. Claude I. Rochat G. M. Hafen No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis BMC Research Notes Cystic fibrosis Pseudomonas aeruginosa Primoinfection Eradication protocol |
author_facet |
F. Claude I. Rochat G. M. Hafen |
author_sort |
F. Claude |
title |
No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis |
title_short |
No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis |
title_full |
No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis |
title_fullStr |
No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis |
title_full_unstemmed |
No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis |
title_sort |
no benefit of longer eradication therapy of pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis |
publisher |
BMC |
series |
BMC Research Notes |
issn |
1756-0500 |
publishDate |
2019-03-01 |
description |
Abstract Objective Patients with cystic fibrosis are more susceptible than members of the general population to lung infections. Infections with Pseudomonas aeruginosa require particular attention, because they may accelerate the deterioration of lung function if not adequately treated. This study assessed the eradication rate of P. aeruginosa primoinfections, with a protocol of inhaled tobramycin and oral ciprofloxacin over a 3 months’ period. Results Retrospective single-center study from June 1st, 2007 to December 31st, 2015. Inclusion of 28 pediatric patients (11 females, 17 males), with a total of 49 primoinfections. Overall success rate of 67.3%, which is similar or even inferior to figures published in the literature. |
topic |
Cystic fibrosis Pseudomonas aeruginosa Primoinfection Eradication protocol |
url |
http://link.springer.com/article/10.1186/s13104-019-4157-8 |
work_keys_str_mv |
AT fclaude nobenefitoflongereradicationtherapyofpseudomonasaeruginosaprimoinfectionsinpediatriccysticfibrosis AT irochat nobenefitoflongereradicationtherapyofpseudomonasaeruginosaprimoinfectionsinpediatriccysticfibrosis AT gmhafen nobenefitoflongereradicationtherapyofpseudomonasaeruginosaprimoinfectionsinpediatriccysticfibrosis |
_version_ |
1725421299362168832 |